Digital immunoassays to reach $7.1b by 2036

Protein biomarker assays will remain the largest segment.

The global digital immunoassays market is set to expand at a compound annual growth rate (CAGR) of 11.4% over the 2026–2036 period, according to a report by Future Market insights.

The firm estimates that market value will rise over the forecast horizon, increasing from $2.4b in 2026 to $7.1b by 2036, based on its assessment of demand for high-precision diagnostic platforms.

Protein biomarker assays will remain the largest segment, accounting for about 44% of total market demand in 2026, reflecting their use in established clinical pathways and routine diagnostic laboratory settings.

Regional forecasts show variation in growth rates, with a 13.8% CAGR projected for India and a 12.5% CAGR for China over the period. The firm also expects the US market to grow at a 10.5% CAGR and the UK market to expand at a 10.0% CAGR.

Adoption of digital immunoassays requires investment in instrumentation, quality control protocols and workforce training, the report noted.

Healthcare systems are incorporating these platforms as part of broader efforts to support automation and data-driven diagnostic workflows.